CN1268626C - 用作mGluR2拮抗剂I的二氢－苯并[b][1,4]二氮杂䓬－2－酮衍生物 - Google Patents

用作mGluR2拮抗剂I的二氢－苯并[b][1,4]二氮杂䓬－2－酮衍生物 Download PDF

Info

Publication number
CN1268626C
CN1268626C CNB028078217A CN02807821A CN1268626C CN 1268626 C CN1268626 C CN 1268626C CN B028078217 A CNB028078217 A CN B028078217A CN 02807821 A CN02807821 A CN 02807821A CN 1268626 C CN1268626 C CN 1268626C
Authority
CN
China
Prior art keywords
phenyl
base
benzo
dihydro
diaza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028078217A
Other languages
English (en)
Chinese (zh)
Other versions
CN1522252A (zh
Inventor
G·亚当
E·格斯啻
V·穆特尔
J·维希曼
T·J·沃特林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1522252A publication Critical patent/CN1522252A/zh
Application granted granted Critical
Publication of CN1268626C publication Critical patent/CN1268626C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNB028078217A 2001-04-12 2002-04-02 用作mGluR2拮抗剂I的二氢－苯并[b][1,4]二氮杂䓬－2－酮衍生物 Expired - Fee Related CN1268626C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01109126.1 2001-04-12
EP01109126 2001-04-12

Publications (2)

Publication Number Publication Date
CN1522252A CN1522252A (zh) 2004-08-18
CN1268626C true CN1268626C (zh) 2006-08-09

Family

ID=8177127

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028078217A Expired - Fee Related CN1268626C (zh) 2001-04-12 2002-04-02 用作mGluR2拮抗剂I的二氢－苯并[b][1,4]二氮杂䓬－2－酮衍生物

Country Status (37)

Country Link
US (1) US6548495B2 (https=)
EP (1) EP1379522B1 (https=)
JP (1) JP4043953B2 (https=)
KR (1) KR100566178B1 (https=)
CN (1) CN1268626C (https=)
AR (1) AR035456A1 (https=)
AT (1) ATE287883T1 (https=)
AU (1) AU2002310912B2 (https=)
BG (1) BG108253A (https=)
BR (1) BR0208887A (https=)
CA (1) CA2441771C (https=)
CZ (1) CZ20033002A3 (https=)
DE (1) DE60202761T2 (https=)
DK (1) DK1379522T3 (https=)
EC (1) ECSP034796A (https=)
ES (1) ES2235044T3 (https=)
GT (1) GT200200072A (https=)
HR (1) HRP20030791B1 (https=)
HU (1) HUP0400991A3 (https=)
IL (2) IL158021A0 (https=)
JO (1) JO2273B1 (https=)
MA (1) MA27011A1 (https=)
MX (1) MXPA03009317A (https=)
MY (1) MY130369A (https=)
NO (1) NO325300B1 (https=)
NZ (1) NZ528345A (https=)
PA (1) PA8543201A1 (https=)
PE (1) PE20021072A1 (https=)
PL (1) PL367086A1 (https=)
PT (1) PT1379522E (https=)
RU (1) RU2270197C2 (https=)
SI (1) SI1379522T1 (https=)
SK (1) SK13692003A3 (https=)
UY (1) UY27259A1 (https=)
WO (1) WO2002083665A1 (https=)
YU (1) YU79103A (https=)
ZA (1) ZA200307242B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2386980C (en) * 1999-10-15 2010-03-16 Geo Adam Benzodiazepine derivatives for use in acute or chronic neurological disorders
AU2004262897B9 (en) * 2003-07-25 2009-12-17 F. Hoffmann-La Roche Ag Combination of mGluR2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders
JP4633123B2 (ja) 2004-11-05 2011-02-16 エフ．ホフマン−ラ ロシュ アーゲー イソニコチン酸誘導体の製造方法
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
BRPI0810655A2 (pt) * 2007-04-19 2014-11-04 Hoffmann La Roche Derivados de di-hidro-benzo[b][1,4] diazepin-2-ona sulfonamida
PL2203439T3 (pl) 2007-09-14 2011-06-30 Addex Pharmaceuticals Sa 1',3'-dipodstawione-4-fenylo-3,4,5,6-tetrahydro-2H, 1'H-[1, 4']bipirydynylo-2'-ketony
US8722894B2 (en) * 2007-09-14 2014-05-13 Janssen Pharmaceuticals, Inc. 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones
US8252937B2 (en) 2007-09-14 2012-08-28 Janssen Pharmaceuticals, Inc. 1,3-disubstituted 4-(aryl-X-phenyl)-1H-pyridin-2-ones
RU2492170C9 (ru) 2007-11-14 2013-12-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Имидазо[1,2-а]пиридиновые производные и их применение в качестве положительных аллостерических модуляторов рецепторов mglur2
JP5547194B2 (ja) 2008-09-02 2014-07-09 ジャンセン ファーマシューティカルズ， インコーポレイテッド． 代謝型グルタミン酸受容体の調節因子としての３−アザビシクロ［３．１．０］ヘキシル誘導体
RU2517181C2 (ru) 2008-10-16 2014-05-27 Орто-Макнейл-Янссен Фармасьютикалз, Инк. Производные индола и бензоморфолина в качестве модулятора метаботропных глутаматных рецепторов
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
CN102439008B (zh) 2009-05-12 2015-04-29 杨森制药有限公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其用于治疗或预防神经和精神病症的用途
MY153912A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 1, 2, 4,-triazolo[4,3-a[pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN103261195B (zh) 2010-11-08 2015-09-02 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
PL2649069T3 (pl) 2010-11-08 2016-01-29 Janssen Pharmaceuticals Inc Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2
EP2661435B1 (en) 2010-11-08 2015-08-19 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
EP2602248A1 (en) 2011-12-05 2013-06-12 University Of Leicester Novel pyrrole compounds
EP2925292A1 (en) 2012-10-23 2015-10-07 F. Hoffmann-La Roche AG Mglu2/3 antagonists for the treatment of autistic disorders
WO2014133022A1 (ja) * 2013-02-28 2014-09-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 テトラヒドロイミダゾ［１，５－ｄ］［１，４］オキサゼピン誘導体
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
KR20220049612A (ko) 2014-01-21 2022-04-21 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
HUE053734T2 (hu) 2014-01-21 2021-07-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk
KR20160143853A (ko) 2014-04-23 2016-12-14 에프. 호프만-라 로슈 아게 지적 장애의 치료를 위한 mglu2/3 길항제
CA2950952C (en) * 2014-06-10 2023-01-10 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (nams) and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU953819A1 (ru) * 1980-08-25 1991-09-23 Физико-химический институт АН УССР 1-(Гидразинокарбонил)алкил-1,2-дигидро-3Н-1,4-бенздиазепин-2-оны, обладающие транквилизирующими и противосудорожными свойствами
MXPA02001340A (es) * 1999-08-05 2004-07-16 Prescient Neuropharma Inc Compuestos novedosos 1,4-benzodiazepina y derivados de los mismos.
CA2386980C (en) * 1999-10-15 2010-03-16 Geo Adam Benzodiazepine derivatives for use in acute or chronic neurological disorders
AU774451B2 (en) * 1999-10-15 2004-06-24 F. Hoffmann-La Roche Ag Benzodiazepine derivatives

Also Published As

Publication number Publication date
ZA200307242B (en) 2004-12-16
KR20030088502A (ko) 2003-11-19
NO20034496L (no) 2003-10-08
SK13692003A3 (sk) 2004-05-04
ES2235044T3 (es) 2005-07-01
IL158021A (en) 2010-04-15
SI1379522T1 (en) 2005-04-30
HUP0400991A2 (hu) 2004-08-30
HUP0400991A3 (en) 2009-06-29
WO2002083665A1 (en) 2002-10-24
EP1379522B1 (en) 2005-01-26
UY27259A1 (es) 2002-10-31
JO2273B1 (en) 2005-04-07
RU2003130648A (ru) 2005-04-10
GT200200072A (es) 2003-06-19
PE20021072A1 (es) 2002-12-07
CA2441771A1 (en) 2002-10-24
BR0208887A (pt) 2004-06-29
BG108253A (bg) 2005-03-31
NO325300B1 (no) 2008-03-25
US20020198197A1 (en) 2002-12-26
HRP20030791A2 (en) 2005-06-30
JP4043953B2 (ja) 2008-02-06
AR035456A1 (es) 2004-05-26
DK1379522T3 (da) 2005-05-30
HRP20030791B1 (en) 2006-06-30
DE60202761T2 (de) 2006-01-12
DE60202761D1 (de) 2005-03-03
ECSP034796A (es) 2003-12-01
KR100566178B1 (ko) 2006-03-29
YU79103A (sh) 2006-05-25
PA8543201A1 (es) 2002-10-31
RU2270197C2 (ru) 2006-02-20
CN1522252A (zh) 2004-08-18
JP2004525965A (ja) 2004-08-26
CZ20033002A3 (cs) 2004-03-17
HK1068339A1 (en) 2005-04-29
MY130369A (en) 2007-06-29
NO20034496D0 (no) 2003-10-08
AU2002310912B2 (en) 2005-06-16
MXPA03009317A (es) 2004-02-12
MA27011A1 (fr) 2004-12-20
IL158021A0 (en) 2004-03-28
PL367086A1 (en) 2005-02-21
PT1379522E (pt) 2005-05-31
US6548495B2 (en) 2003-04-15
NZ528345A (en) 2005-04-29
EP1379522A1 (en) 2004-01-14
CA2441771C (en) 2008-12-30
ATE287883T1 (de) 2005-02-15

Similar Documents

Publication Publication Date Title
CN1268626C (zh) 用作mGluR2拮抗剂I的二氢－苯并[b][1,4]二氮杂䓬－2－酮衍生物
CN1264825C (zh) 用作mGluR2拮抗剂Ⅱ的二氢－苯并[b][1,4]二氮杂䓬－2－酮衍生物
CN1195522C (zh) 苯并二氮杂䓬衍生物
CN1199954C (zh) 苯并二氮杂䓬衍生物
CN1093124C (zh) 对PPAR－γ具有激动剂活性的取代的4－羟基－苯基alcanoic acid衍生物
CN1114596C (zh) 联苯基衍生物
CN1020903C (zh) 新颖的(1h-咪唑-1-基甲基)取代的苯并咪唑衍生物的制备方法
CN1281604C (zh) 取代吡唑化合物
CN1633430A (zh) 用于治疗神经紊乱的二氢苯并二氮杂䓬－2－酮衍生物
CN1700918A (zh) 关于hiv整合酶的n－取代的羟基嘧啶酮甲酰胺抑制剂
CN1832928A (zh) 以5元杂环为基础的p38激酶抑制剂
CN1678579A (zh) 吲哚－3－硫衍生物
CN1950365A (zh) 作为肝脏－x－受体调节剂的吲哚基衍生物
CN1129443A (zh) 仲胺用作治糖尿病和治肥胖病药物
CN1505613A (zh) 取代的吲哚、含这类吲哚的药物组合物及它们作为PPAR-γ结合剂的用途
CN1514833A (zh) 新型酪氨酸激酶抑制剂
CN1423633A (zh) 氮杂环丁烷衍生物、其制备方法及其药物组合物
CN1404479A (zh) 新的1,3－二氢－2h－吲哚－2－酮衍生物,它们的制备方法以及含有它们的药物组合物
CN1121717A (zh) 杂环化合物及其制备方法和用途
CN1337952A (zh) 作为基质金属蛋白酶抑制剂的2,3,4,5－四氢－1h－[1,4]苯并二氮杂草－3－异羟肟酸
CN1193966A (zh) 芳族化合物和含有它们的药物组合物
CN1419541A (zh) 作为bax抑制剂的药物活性的吡咯烷衍生物
CN1780822A (zh) 2,4－二氢－[1,2,4]三唑－3－硫酮衍生物作为酶髓过氧化物酶(mpo)抑制剂的用途
CN1293663A (zh) 为基质金属蛋白酶抑制剂的2,3,4,5－四氢－1h－[1,4]苯并二氮杂䓬－3－异羟肟酸
CN1069974A (zh) 三唑基取代的叔胺化合物及其盐

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1068339

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060809

Termination date: 20150402

EXPY Termination of patent right or utility model